On February 3, 2026, the Company completed the acquisition of the Erigen Assets (the 'Erigen Closing') under the Asset Purchase Agreement (the 'Asset Acquisition') and issued to Erigen 8,268,495 shar…
Pursuant to an engagement letter, H.C. Wainwright & Co., LLC (the “ Placement Agent ”) acted as the exclusive placement agent in connection with the foregoing transaction, and the Company issued to t…
We are obligated to pay Novatim up to $80 million in total upon achievement of certain development milestones for the programs and up to $1.24 billion in total upon achievement of certain commercial …
The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the 'Rights Agreement'), between the Company and Computershare Trust Company, NA.
We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
Tempest Therapeutics, Inc. Customers
No clients on recordNo downstream customers found in our database for Tempest Therapeutics, Inc..
Tempest Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TPST-DEBT-13083
Warrants outstanding: 6784989
90%
xbrl warrant detail from xbrl 2026-02-03.
TPST-DEBT
Debt stack $8.1M
90%
Market cache reports total debt of $8.1M.
TPST-DEBT-13084
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Tempest Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Tempest Therapeutics, Inc..
Tempest Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
TPST-OWNER-VERSANT-VENTURE-MANAGEMENT-LLC
Versant Venture Management, LLC
90%
13F overlay lists Versant Venture Management, LLC as top holder; 1 tracked holders.
Tempest Therapeutics, Inc. Extended Supply Chain Network